Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progenics reports successful early-stage trial for HIV drug
Patients receiving a single 5mg/kg dose of PRO 140 achieved an average maximum decrease of viral concentrations in the blood of 98.5%, with individual reductions ranging up to
Patients receiving a single 5mg/kg dose of PRO 140 achieved an average maximum decrease of viral concentrations in the blood of 98.5%, with individual reductions ranging up to
In the study, a total of 40 healthy subjects were exposed to DG051 at doses up to 320mg per day for seven days. DG051 was well tolerated at
As a result, the ruling upholding the patent is now final, according to San Diego-based Vical. Vijay Samant, Vical’s president and CEO, said: “We are pleased that the
Dr Sophie Combe, VP of clinical development at Trigen, said: “Based on the promising results of this first-in-man study, investigation of PR-15 in patients is warranted to further
In two large, multinational, double-blind, randomized phase III clinical studies that enrolled and treated 1,867 patients in total, 719 of whom had infections with methicillin-resistant Staphylococcus aureus (MRSA),
FTY720 (fingolimod) is a novel, investigational, once-daily, oral medication, in relapsing-remitting multiple sclerosis (RRMS). The 12-month, double-blind, randomized, active-comparator study will include approximately 1275 MS patients in more
Paladin said that BioEnvelop Inc has expertise in developing and manufacturing rapidly dissolving edible films for the nutraceutical and pharmaceutical markets in Canada and the US. Paladin has
The appellate court issued an order prohibiting regulatory approval of Novopharm's product in Canada until Celebrex's compound patent expires in November 2014. Pfizer's general counsel, Allen Waxman, said:
The company plans to begin a phase I trial investigating PEG-SN38 in patients with solid tumors or lymphoma in the fist half of this year. PEG-SN38 is the
GED-aPC is an engineered analog of recombinant human activated Protein C with enhanced anti-inflammatory, anti-thrombotic and strong binding to endothelial protein C receptor properties, and has broad potential